{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:13:14Z","timestamp":1779343994222,"version":"3.51.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>With the increasing use of bispecific T cell engagers (BiTEs) in anti-tumor immunotherapy, the associated adverse reactions pose significant challenges to clinical application. Nervous system toxicity (NST) is one of the notable adverse events associated with this class of drugs. This study aims to provide a comprehensive analysis of BiTE-induced nervous system adverse events. Improving the diagnosis and monitoring of these adverse events is crucial for the early identification and treatment of NSTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilized the FAERS database to analyze NSTs associated with BiTEs reported between January 2004 and September 2025. Positive safety signals of the drugs were assessed using four commonly applied disproportionality analysis methods. In addition, the time to onset of drug-induced adverse reactions was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 15,558 patients who developed NSTs during BiTE therapy were included in this study. The average age at NST onset was 51.12 \u00b1 24.44 years. The incidence was 21.19% higher in men than in women (6,139 men vs. 5,065 women), with the United States reporting the highest proportion of cases (50.68%). Among the BiTEs analyzed, blinatumomab accounted for the highest number of reported cases (49.63%). The NSTs observed include immune effector cell-associated neurotoxicity syndrome and other forms of neurotoxicity. Tremor, seizures, and nervous system disorders were reported more frequently with blinatumomab. In the comparative analysis of drug induction time, glofitamab exhibited the longest induction time [82.00 days (range, 1\u223c1190)], whereas tarlatamab showed the shortest time [16.70 days (range, 1\u223c141)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>BiTEs have the potential to induce significant adverse events within the central nervous system and may exacerbate pre-existing conditions. Given the increasing utilization of BiTEs, it is essential to integrate resources such as the FAERS database to effectively monitor adverse reactions associated with these novel therapeutic agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1819689","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:45:35Z","timestamp":1779342335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse neurological events associated with bispecific T cell engagers in oncology: a real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Qianqian","family":"Cui","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People\u2019s Hospital","place":["Yichang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangqi","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, Guangdong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxiao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People\u2019s Hospital","place":["Yichang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101649","DOI":"10.1016\/j.beha.2025.101649","article-title":"Bispecific T-cell engager therapy for multiple myeloma","volume":"38","author":"Cirstea","year":"2025","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/nbt.3349","article-title":"Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1","volume":"33","author":"Dao","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12916-025-03913-6","article-title":"Adverse events in the nervous system associated with blinatumomab: a real-world study","volume":"23","author":"Gao","year":"2025","journal-title":"BMC Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/nejmoa2411680","article-title":"Blinatumomab in standard-risk B-Cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.clinthera.2025.09.001","article-title":"Real-world hepatobiliary toxicity after bispecific T-Cell engager therapy: a 10-Year disproportionality analysis of the food and drug administration adverse event reporting system and the world health organization's global individual case safety report database","volume":"47","author":"Hu","year":"2025","journal-title":"Clin. Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/jco.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-Targeting T-Cell-Engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-Cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/mt.2014.156","article-title":"Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells","volume":"23","author":"Iwahori","year":"2015","journal-title":"Mol. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","article-title":"Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events","volume":"80","author":"Klinger","year":"2020","journal-title":"Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/ejh.14353","article-title":"Talquetamab in multiple myeloma: efficacy, safety, and future directions","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2425781122","DOI":"10.1073\/pnas.2425781122","article-title":"Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency","volume":"122","author":"Leithner","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/s1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the european myeloma network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.3390\/curroncol30070467","article-title":"Toxicity profile of chimeric antigen receptor T-Cell and bispecific antibody therapies in multiple myeloma: pathogenesis, prevention and management","volume":"30","author":"Markouli","year":"2023","journal-title":"Curr. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/jcpt.13741","article-title":"The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials","volume":"47","author":"Mocquot","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-Targeted bispecific T-Cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-Year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival","volume":"29","author":"Topp","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41551-024-01202-w","article-title":"Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager","volume":"8","author":"Yang","year":"2024","journal-title":"Nat. Biomed. Eng."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1819689\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:45:37Z","timestamp":1779342337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1819689\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":27,"alternative-id":["10.3389\/fphar.2026.1819689"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1819689","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1819689"}}